Imclone Systems


Also found in: Financial, Wikipedia.
A biopharmaceutical company which developed a portfolio of immunotherapies for colorectal and other cancers; its lead compound, Erbitux, received FDA approval after a Wall Street drama
References in periodicals archive ?
one of New Jersey's fastest growing general contracting firms, has recently completed a high-end renovation project on behalf of ImClone Systems Incorporated at 33 Chubb Way in Branchburg, N.
DARMSTADT, Germany and NEW YORK -- In response to earlier reports, Merck KGaA and ImClone Systems today reiterated Merck KGaA's commitment to sharing clinical data with its partner, ImClone Systems in support of the resubmission in the United States of the Biologics License Application (BLA) for Erbitux(TM) for the treatment of irinotecan-refractory colorectal cancer.
Company analysis includes a history of ImClone Systems, a business segment analysis of the segments ImClone Systems operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company's major competitors.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Bear Stearns 3rd Annual Biotech Confab in Boston, MA on June 7, 2007 from 4:50 PM to 5:15 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the Citigroup 2007 Healthcare Conference in New York, NY on Thursday, May 24, 2007 from 12:00 PM to 12:25 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference from 11:00 AM to 11:40 AM Eastern Time today.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Lehman Brothers 10th Annual Global Healthcare Conference in Miami, Florida on Wednesday, March 21, 2007 from 10:45 AM to 11:10 AM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Merrill Lynch Eighteenth Annual Global Pharmaceutical, Biotechnology and Medial Device Conference on Tuesday, February 6, 2007 from 2:20 PM to 3:00 PM Eastern Time.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it expects to disclose the result of a Phase III study of ERBITUX([R]) (cetuximab) plus FOLFIRI (an irinotecan-based chemotherapy) in patients with previously untreated metastatic colorectal cancer, before the end of the week of January 8, 2007.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) today announced the commencement of patient treatment in a Phase I clinical trial of its fully human IgG1 monoclonal antibody targeting the platelet derived growth factor receptor alpha (PDGFR[eth]), IMC-3G3, in patients with solid tumors.
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the 25th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2007, from 10:00 AM to 10:30 AM Pacific Time.